Background-Pulmonary arterial hypertension (PAH) is a rare but important cause of morbidity and mortality in children. Methods and Results-We analyzed data from 216 patients Յ18 years of age at diagnosis who were enrolled in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Median age at diagnosis and enrollment was 7 and 15 years, respectively. The most frequent presenting symptom was dyspnea (idiopathic/familial PAH, 53%; PAH associated with congenital heart disease, 30%). Presyncope/syncope was more frequent in patients with idiopathic PAH/familial PAH (36%) than in those with PAH associated with congenital heart disease (4%). At diagnosis, mean pulmonary artery pressure and pulmonary vascular resistance index were 56 mm Hg and 17 Wood units ⅐ m 2 , respectively. Five-year survival from diagnosis for the overall cohort was 74Ϯ6%, with no significant difference between the idiopathic PAH/familial PAH (nϭ122, 75Ϯ7%) and PAH associated with congenital heart disease (nϭ77, 71Ϯ13%) cohorts (Pϭ0.53). Older age at diagnosis was the only variable significantly associated with decreased survival from diagnosis. Variables at enrollment that were significantly associated with decreased survival from enrollment included higher pulmonary vascular resistance index, lower-weight z scores, and familial PAH. Additional variables at enrollment, identified in a secondary analysis, that were marginally associated with increased survival from enrollment included acute vasoreactivity (adaptation of conventional pediatric definition; Pϭ0.087) and lower brain natriuretic peptide (Pϭ0.060). None of the 22 patients who were acute responders treated with high-dose calcium channel blockade as monotherapy or combination therapy died within 5 years of diagnosis. Conclusion-Using REVEAL, we identified key predictors of survival in childhood PAH. Refining these prognostic parameters should help clinicians improve outcomes. Clinical Trial Registration-URL: www.clinicaltrials.gov. Unique identifier: NCT00370214. (Circulation. 2012;125:113-122.) 
P ulmonary arterial hypertension (PAH), an important cause of morbidity and mortality, is characterized by increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP). 1 With an estimated prevalence of 15 to 50 cases per 1 million adults, PAH is a rare disease. 2 PAH is even less common in children, with an estimated prevalence of Ͻ10 cases per 1 million children. 3 Treatment options for children with PAH have been extrapolated from evidence-based adult guidelines. Although the clinical features and course may differ at times between pediatric and adult patients with PAH, limited data suggest that the use of medications approved for the treatment of adults favorably affects children with PAH. 4 Additionally, recent observational studies have identified prognostic parameters for adults with PAH 5 ; however, prognostic indicators in children are poorly understood. To date, the literature on pediatric PAH has been limited primarily to relatively small sample sizes from single centers. A broader description of current clinical characteristics, treatment patterns, and outcomes of childhood PAH is not yet available to inform physicians.
Clinical Perspective on p 122
The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) is a large observational study of children and adults diagnosed with PAH at medical centers distributed across the 4 major census regions of the United States. In contrast to clinical trials, which often are only several months in duration and have restrictive enrollment criteria, REVEAL aims to provide long-term observations of a broader PAH patient population. In this article, we describe the demographic and hemodynamic characteristics, treatment, and survival of children diagnosed with PAH who are enrolled in REVEAL.
Methods

Study Design and Population
The design and baseline characteristics of REVEAL have been described previously. 4, 6 Pediatric patients (age, Ն3 months and Յ18 years at diagnosis) were followed up at 26 of the 55 REVEAL sites. REVEAL was initiated before the Fourth World Symposium on Pulmonary Hypertension 7, 8 ; accordingly, patient categorization conforms to the Third World Symposium on Pulmonary Hypertension. 9 Study objectives and methods were prespecified in an Institutional Review Board-approved protocol, and all participants or their legal guardians gave written informed consent (and assent as appropriate).
Inclusion Criteria
PAH was defined as mean PAP Ն25 mm Hg at rest, pulmonary capillary wedge pressure Յ15 mm Hg, and PVR Ն3 Wood units. The date of diagnosis was defined as the date of the right heart catheterization (RHC) confirming these criteria. Both newly diagnosed (diagnostic RHC within 3 months before enrollment) and previously diagnosed patients were enrolled. Patients were categorized by PAH subgroups: idiopathic PAH (IPAH); familial PAH (FPAH); PAH associated with connective tissue disease, congenital heart disease (APAH-CHD; repaired or unrepaired), human immunodeficiency virus, portal hypertension (APAH-PoPH), and drugs/ toxins; and persistent pulmonary hypertension of the newborn. Descriptive statistics for treatments at enrollment exclude patients in blinded trials for whom treatment data were not collected.
We examined 2 definitions of acute vasoreactivity: the adult consensus definition, agreed on at the Third and Fourth World Symposia, 10 including a decrease in mean PAP Ն10 mm Hg reaching Ͻ40 mm Hg with an increase or no change in cardiac output and (2) an adaptation of the conventional pediatric criteria 11, 12 including a decrease in mean PAP Ն20%, an increase or no change in cardiac index (CI), and a decrease or no change in the ratio of PVR to systemic vascular resistance, which we modified to allow for clinically insignificant decreases in CI. Standardized z scores for weight and height were derived from age-and sex-based standards from the National Center for Health Statistics. 13
Statistical Analysis
Descriptive statistics are provided for subgroup comparisons, including number and percentage of nonmissing values for categorical data and meanϮSD for continuous variables. Medians rather than means were reported for continuous variables with a skewed distribution. Pulmonary and systemic blood flows were calculated with the Fick method (with oxygen consumption estimated by the method of LaFarge and Miettinen) for patients with APAH-CHD with unrepaired or partially repaired lesions. For all other patients, either the Fick or thermodilution methods were used. P values for descriptive group comparisons were obtained with the Fisher exact test. The 2-sample t test was used when data were approximately normally distributed, and the 2-sample Wilcoxon rank-sum test was used for variables that were not normally distributed. Two-year Kaplan-Meier survival estimates (ϮSE) from enrollment were calculated for subgroups, and P values were obtained by log-rank. P values were calculated for hazard ratios (HRs) for IPAH/FPAH versus APAH-CHD from Cox proportional hazard models. Patients who had undergone transplantation were not censored, and follow-up continued after transplantation. A secondary analysis was performed with the end point of transplant-free survival.
Five-year Kaplan-Meier survival estimates from time of diagnostic RHC, accounting for left truncation, 14 were calculated for the combined IPAH/FPAH and APAH-CHD subgroups and for each of these 2 subgroups separately. Left truncation arises when patient information is gathered retrospectively. When the outcome of a study is survival from diagnosis, many patients may not be enrolled in the study until months or years after diagnosis. By having survived to enrollment, these patients could not have had an event between diagnosis and enrollment and therefore are removed from the risk set between those 2 time points.
The impact of candidate predictors of survival from the time of diagnostic RHC and from the time of enrollment was examined with Cox proportional hazards models. Proportional hazards assumptions were confirmed with a Kolmogorov-type supremum test. 15 Survival models from the time of diagnostic RHC accounted for left truncation. All variables with individual values of PϽ0.20 were entered into a stepwise multivariable Cox regression to include a broad range of variables. Multiple imputation was used to fill in missing data for candidate predictors in the multivariable models and to generate valid statistical estimates of error. 16 
Results
Patient Characteristics
Twenty-six sites followed up 216 consecutively enrolled children with PAH confirmed by RHC. Newly and previously diagnosed patients were enrolled from March 2006 to September 2007 with additional newly diagnosed patients consecutively enrolled through December 2009. The data lock was November 19, 2010.
The IPAH/FPAH and APAH-CHD subgroups combined accounted for 199 of the total 216 patients (92%; IPAH/ FPAH, nϭ122; APAH-CHD, nϭ77 [repaired, nϭ29; unrepaired/partial repair, nϭ48]). The remaining 8% were divided among the other group 1 PAH subgroups: PAH associated with connective tissue disease (nϭ10), APAH-PoPH (nϭ3), persistent pulmonary hypertension of the newborn (nϭ3), and other APAH (nϭ1). Of the 199 patients in the IPAH/FPAH and APAH-CHD subgroups, 108 (54%) were diagnosed after 2001, 58 (29%) were diagnosed from 1995 to 2001, and 33 (17%) were diagnosed before 1995. These divisions are based on eras of PAH drug availability in the United States. No PAH-specific drugs were approved before 1995; epoprostenol was the only approved drug from 1995 to 2001; and additional drugs have been approved since 2001. A total of 30 patients (14%) were newly diagnosed at enrollment.
Demographics
Demographic characteristics of the patients stratified by subgroup are shown in Table 1 . Overall, 64% were female. The most frequent initial presenting symptom in both subgroups was dyspnea on exertion (IPAH/FPAH, 53%; APAH-CHD, 30%). Presyncope/syncope was more frequent in IPAH/FPAH patients compared with APAH-CHD patients (36% versus 4%, respectively; PϽ0.001). The median time from onset of symptoms to diagnostic RHC was 8 months for both the APAH-CHD and IPAH/FPAH cohorts. Fifty-two percent of children with available data were in New York Heart Association/World Health Organization functional class I or II at the time of diagnosis.
Hemodynamic Parameters
Hemodynamic data are presented in Table 2 . The patients had marked elevations in mean arterial pressure and PVR index (PVRI) that were higher for IPAH/FPAH than for APAH-CHD (mean arterial pressure, 73Ϯ17 versus 68Ϯ14 mm Hg, respectively, Pϭ0.044; PVRI, 19Ϯ17 versus 13Ϯ9 Wood units ⅐ m 2 , respectively, Pϭ0.014). Mean right atrial pressure #The adult consensus definition of acute vasoreactive response is defined as a decrease in mean pulmonary artery pressure (mPAP) of at least 10 mm Hg to a peak vasoreactivity value Ͻ40 mm Hg, combined with an increase or no change in cardiac output. Four of 60 APAH-CHD patients and 19 of 102 IPAH/FPAH patients who underwent acute vasodilator testing were acute responders using the adult consensus definition.
**The adaptation of the conventional pediatric definition of an acute vasoreactive response is defined as a decrease in mPAP of at least 20% and an increase or no change in cardiac index (CI) and a decrease or no change in the ratio of pulmonary to systemic vascular resistance. Unlike the adult definition criteria, decreases in CI are permitted if the value remains within normal limits (2.5-4.0 L ⅐ min Ϫ1 ⅐ m Ϫ2 ) and the decrease in CI is not clinically significant. Nine of 60 patients with APAH-CHD and 36 of 102 patients with IPAH/FPAH were acutely vasoreactive according to the adaptation of the original pediatric definition.
† †Seven patients with APAH-CHD and 30 patients with IPAH/FPAH had available data for the 6-minute walk test distance (6MWD) at diagnosis. ‡ ‡These patients were identified as having a diagnosis of asthma at the time of PAH diagnosis.
was not elevated in either patients with IPAH/FPAH or APAH-CHD patients. CI was normal in 39% of the IPAH/ FPAH patients and 53% of APAH-CHD patients.
Acute Vasoreactivity
Among the patients with IPAH/FPAH (nϭ122) and APAH-CHD (nϭ77), 162 underwent acute vasodilator testing (AVT). According to the adaptation of the conventional pediatric definition, 11 Among the 43 patients who were receiving CCBs for PAH at enrollment, either as monotherapy or as part of combination therapy, 42 (98%) had undergone AVT and 1 (2%) had not. Of those 42 who underwent AVT and were on CCBs, 13 (31%) were acute responders with the adult consensus definition and 22 (52%) were acute responders according to the adaptation of the conventional pediatric definition (including 23 patients by either definition, 12 of whom were acute responders with both definitions). At enrollment, the 13 acute responders with the adult consensus definition included 7 patients treated with CCBs alone and 6 patients treated with CCBs as part of combination therapy. Among the 22 acute responders (adaptation of conventional pediatric definition), 13 were treated with CCB monotherapy at enrollment and 9 with CCBs as part of combination therapy at enrollment.
Treatments
A breakdown of PAH treatments at enrollment is shown in Table 3 . Phosphodiesterase type-5 inhibitors were prescribed for 64% of IPAH/FPAH patients compared with 45% of APAH-CHD patients (Pϭ0.012). Prostacyclin analogs were †Other PAH: PAH associated with connective tissue disease (nϭ10), PAH associated with portal hypertension (nϭ3), persistent pulmonary hypertension of the newborn (nϭ3), and PAH associated with hereditary hemorrhagic telangiectasia (nϭ1).
‡P values are calculated with 2-sample t tests assuming equal variances. The P values assess only the 2-group comparison between CHD and IPAH/FPAH. §mPCWP at rest if available is given; otherwise, left ventricular end-diastolic pressure at rest is given. Pulmonary and systemic blood flows are calculated from the Fick equation for patients with unrepaired CHD shunts or for those with residual shunts. For all others, pulmonary and systemic blood flows are equal, ie, cardiac index, and were calculated by either Fick or thermodilution.
#For patients with APAH-CHD with unrepaired/partial lesion, SVO 2 is O 2 saturation proximal to shunt. For all others, SVO 2 is myocardial oxygen consumption.
used in 50% of IPAH/FPAH patients compared with 28% of APAH-CHD patients (Pϭ0.004). More APAH-CHD patients were on monotherapy (49%) than dual (24%) or triple (5%) therapy, whereas similar proportions of IPAH/FPAH patients were on either monotherapy (37%) or dual therapy (35%), and 16% were on triple therapy.
Survival
There were 6 transplantations and 27 deaths (including 3 after transplantation) among the 199 patients in the IPAH/FPAH and APAH-CHD cohorts. There were 4 deaths among the 17 patients not included in the IPAH/FPAH and APAH-CHD cohorts (connective tissue disease, 2; PoPH, 2). Median follow-up in the entire cohort was 42 months (range, 0 -51 months) with 1-, 3-, and 5-year estimated survival rates from diagnostic RHC of 96Ϯ4%, 84Ϯ5%, and 74Ϯ6%, respectively ( Figure 1 ). Survival within the 5 years after diagnostic RHC was similar between IPAH/FPAH and APAH-CHD (75Ϯ7% versus 71Ϯ13%; Pϭ0.53; Figure 5 ). Five-year survival from diagnostic RHC for repaired and unrepaired CHD was 60Ϯ19% and 83Ϯ14%, respectively. The findings in the secondary analysis of transplantation-free survival were similar to those of the overall 5-year survival. The large SE for the APAH-CHD subgroup and very large SE for the additional stratification of the APAH-CHD subgroup reflect limited sample size available for estimating the critical first year of the survival curve. There were no statistically significant differences in outcomes between incident and prevalent patients. None of the 22 patients who were acute responders according to the adaptation of the conventional pediatric definition treated with CCBs as monotherapy or as part of combination therapy died during the first 5 years after diagnostic RHC. One additional surviving patient was an acute responder only by the adult consensus definition and was on a medical regimen that included a CCB.
Two-year survival from enrollment for the IPAH/FPAH and APAH-CHD cohorts (nϭ199) was 88Ϯ2% and was similar for IPAH/FPAH and APAH-CHD (Pϭ0.60 for time to event; 2-year survival estimated as 90Ϯ3% versus 85Ϯ4%; Figure 2 ). Two-year survival from enrollment was also similar for APAH-CHD repaired compared with unrepaired/ partially repaired (Pϭ0.77 for time to event; 2-year survival estimated as 86Ϯ7% versus 85Ϯ5%; Figure 3 ). However, when IPAH and FPAH are compared, 2-year survival from enrollment appeared better for IPAH than for FPAH (Pϭ0.045 for time to event; 2-year survival estimated as 92Ϯ3% versus 71Ϯ12%; Figure 4 ).
Univariable Cox proportional hazards regression models of estimated survival from diagnostic RHC or from enrollment are presented in Table 4 . Variables assessed at diagnostic RHC that were associated with increased mortality from diagnostic RHC (PϽ0.10) were older age, lower CI, higher PVRI, and lack of AVT response (as defined by adaptation of the original pediatric definition). Stepwise multivariable analysis identified only older age at diagnostic RHC (HRϭ1.51 per 5 years of age; Pϭ0.006) as a predictor of increased mortality from diagnostic RHC. A sensitivity analysis of the most common PAH subgroups (IPAH/FPAH and APAH-CHD) also identified lower-height z scores as a prognostic parameter. Estimates of survival from enrollment were based on the most recent measurements before enrollment, which included the diagnostic RHC for those patients who did not have a subsequent RHC before enrollment (75 of 199, 38%). Predictors of increased mortality from the stepwise enrollment multivariable model were higher PVRI (HRϭ1.15 per 5 Wood units ⅐ m 2 ; PϽ0.001), lower-weight z score (HRϭ0.71; Pϭ0.005), and FPAH (HRϭ3.22; Pϭ0.043). In a secondary analysis in which marginal predictors were included in the model, low brain natriuretic peptide Ͻ50 pg/mL or N-terminal pro-brain natriuretic peptide Ͻ300 pg/mL (HRϭ0.38; Pϭ0.060) and acute vasoreactivity (HRϭ0.32; Pϭ0.087, according to the adaptation of the conventional pediatric definition) suggest utility as prognostic parameters of decreased mortality. The results are similar when the 17 
Discussion
The pediatric REVEAL cohort is the most comprehensive prospective database of group 1 childhood PAH reported to date. The size of the study (nϭ216), number of referral sites (nϭ26), and geographical distribution make the observations generalizable to clinical US practice. Five-year survival from diagnostic RHC was 74%, considerably better than historical control subjects in pediatric PAH 1, 12, 20, 21 and consistent with other recent reports. 12, 20, 22, 23 Survival from diagnostic RHC in the pediatric REVEAL cohort was similar for IPAH/FPAH and APAH-CHD, in contrast to natural history data indicating that patients with Eisenmenger syndrome had a far better survival than patients with IPAH. 24 Prospective, long-term, observational studies reflecting current practice should help us evaluate whether the reduction of difference in survival between IPAH/FPAH and APAH-CHD is due to treatment differences between these 2 subgroups.
Despite educational efforts for earlier diagnosis, a significant delay persists from the onset of symptoms to diagnosis. The most frequent initial symptom was dyspnea on exertion; however, this was reported in only 53% of patients with IPAH/FPAH and even less frequently in those with APAH-CHD (30%). The 2 most frequent initial complaints in APAH-CHD, dyspnea on exertion and fatigue, may not have been significant concerns to the parents because these symptoms had "always been present" and were thus thought to represent "normal" behavior. Presyncope/syncope was the second most frequent symptom (36%) at presentation in the IPAH/FPAH cohort. However, the frequency of presyncope/ syncope in the APAH-CHD cohort was only 4%.
Although all children had significant PAH at presentation, they rarely presented with right-side heart failure or significant limitations affecting activities of daily living. Accordingly, at diagnosis, half of the patients were in functional class I or II with normal right heart function. These findings are in marked contrast to findings in adults in REVEAL. 4 Consistent with these observations, exercise capacity, assessed by the 6-minute walk distance test, was often within normal range for the children and greater than in adults with similarly increased mean PAP and PVRI.
We found a significant increase in mortality from the time of diagnostic RHC among older children (ie, those diagnosed at a later age had a worse prognosis). Aside from age at diagnosis, the strongest predictors of increased mortality from the time of diagnostic RHC were lower CI, higher PVRI, and lack of an acute response with AVT (adaptation of conventional pediatric definition). Previous studies have reported that younger age at diagnosis and acute vasoreactivity at both diagnosis and follow-up are prognostic indicators for children with IPAH/FPAH. 12, 23 Pediatric data from the United Kingdom have recently reported novel prognostic parameters: Low weight and height (growth retardation) predict a poor outcome. 25 In addition, van Loon et al 22 reported that worse functional class (ie, higher functional class), higher ratio of mean PAP to mean arterial pressure, higher brain natriuretic peptide, higher uric acid, lower CI, and lower systolic blood pressure at diagnosis are prognostic. Reassessment of disease severity on treatment has also been shown to be important in assessing prognosis in adults. 5 For patients with a positive AVT response, consideration of long-term high-dose CCB therapy is recommended by both adult and pediatric consensus guidelines. 19, 26 However, the likelihood of an acute response in adults with IPAH/FPAH is Ͻ10% and is even less frequent for FPAH. 27, 28 In contrast, acute vasoreactivity is significantly higher in children: The acute response rate was 35% in the REVEAL pediatric IPAH/FPAH cohort, consistent with the 40% response rate reported by Yung et al 23 and Rosenzweig et al 28 ; thus, performing AVT in children remains important because acute responders can do extremely well on long-term high-dose CCBs either as monotherapy or as part of combination PAH therapy. None of the 22 responders treated with CCBs as monotherapy or as part of combination therapy died within 5 years after diagnosis, consistent with the 97% 5-year survival rate reported by Yung et al 23 ; however, the 10-year survival rate was 81%, reinforcing the need to follow up these patients closely over the long term. The REVEAL pediatric data suggest that using the adaptation of the conventional pediatric definition for an acute responder appears to be the most reasonable approach at this time to determine who should be considered for initial treatment with long-term high-dose CCB therapy and for identifying patients who appear more likely to have a favorable outcome. These data also suggest that the most recent adult consensus definition for defining an acute responder to AVT may fail to identify some children who could do extremely well with long-term CCBs either as monotherapy or as part of combination therapy. This important observation needs confirmation.
A limitation of this study is that most of the patients belong to either the IPAH/FPAH or the APAH-CHD subgroup; insufficient data are available to state confidently that our findings for the overall REVEAL pediatric PAH cohort apply equally well to rare subgroups in pediatric PAH such as APAH-PoPH. This registry also includes a survival bias in that most of the patients were previously diagnosed. Thus, the characterization of the population and estimated survival from enrollment are directly generalizable only for previously diagnosed patients or a population such as REVEAL and those seen commonly in clinical practice where newly diagnosed patients are a minority. The estimated survival from diagnostic RHC, which uses a delayed entry model, is applicable to newly diagnosed patients. Interpretation of treatments is limited by the uncontrolled nature of any registry. Nevertheless, the large sample size, broad representation, and longitudinal follow-up should prove invaluable. Finally, only a relatively few deaths occurred (nϭ31 of the total 216 patients), which limited our ability to identify prognostic parameters and restricted the primary multivariable analysis to only 3 predictors. However, this should not rule out other parameters as unimportant in predicting outcomes; further research is critical to confirm or refute the findings of our sensitivity analyses, which included parame- #Heart rate and systolic blood pressure (SBP) were measured during right-side heart catheterization (RHC). There were not enough heart rate data available for the univariable model to be estimated. **These variables were created at the time of PAH diagnosis if data were available; otherwise, they were based on data at the time of enrollment. † †The adult definition of acute vasoreactive response is defined as a decrease in mean pulmonary artery pressure (mPAP) of at least 10 mm Hg to an absolute value Ͻ40 mm Hg, combined with an increase or no change in cardiac output. Too few patients met this criterion to accurately estimate the hazard over a long period of time. The adapted conventional pediatric definition of an acute vasoreactive response is defined as a decrease in mPAP of at least 20% and an increase or no change in cardiac index and a decrease or no change in the ratio of pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR); decreases in cardiac index (if not clinically significant) were permitted if the value remained within normal limits: 2.5-4.0 L ⅐ min Ϫ1 ⅐ m Ϫ2 . ‡ ‡Presyncope/syncope is a check box on the PAH-specific medical history form for initial symptoms later attributed to PAH. § §All variables with values of PϽ0.20 were entered into a stepwise multivariable Cox proportional hazards regression. The primary multivariable model from the time of PAH diagnosis included only 1 term: age (hazard ratio ͓HR͔ϭ1.51 per 5 years; Pϭ0.006). A sensitivity analysis excluding the 17 non-IPAH/FPAH or APAH-CHD patients included both age (HRϭ1.85; Pϭ0.001) and z score for height (HRϭ0.73; Pϭ0.015). The primary multivariable model from the time of enrollment also included 3 terms: PVR index (HRϭ1.15 per 5 Wood units ⅐ m 2 ; PϽ0.001), z score for weight (HRϭ0.71; Pϭ0.005), and FPAH (HRϭ3.22; Pϭ0.043). A secondary model including marginally significant predictors included 5 terms: PVR index (HRϭ1.16 per 5 Wood units ⅐ m 2 ; Pϭ0.003), z score for weight (HRϭ0.73; Pϭ0.011), FPAH (HRϭ4.93; Pϭ0.008), BNP Ͻ50 pg/mL or N-terminal-proBNP (NT-proBNP) Ͻ300 pg/mL (HRϭ0.38; Pϭ0.060), and acute vasoreactivity (adapted conventional pediatric definition; HRϭ0.32; Pϭ0.087).
ters that, although not statistically significant at this time, may turn out to be statistically significant with longer follow-up and an inevitable increase in events.
From the observations from the REVEAL pediatric cohort, we identified key predictors of survival in childhood PAH. Refining these parameters should help clinicians improve outcomes for their pediatric patients. REVEAL should also increase disease awareness and facilitate earlier referral to an experienced pediatric center. With recent adult data supporting early treatment, 29 we hope that by seeing children earlier and starting treatment sooner, we will make further progress in improving outcomes for pediatric PAH.
